Everest Medicines Ltd

Everest Medicines has a liquidity position that is characterized by a current ratio of 4.89, indicating a strong short-term liquidity buffer. However, the company reported negative operating cash flow of -92.56 million CNY and free cash flow of -489.59 million CNY, suggesting ongoing cash burn despite a cash and equivalents balance of 727.48 million CNY. The company's debt-to-equity ratio is 0.17, reflecting a relatively low leverage position. Profitability metrics for Everest Medicines are negative, with a return on equity of -5.61% and a return on assets of -4.36%. These figures indicate that the company is not generating returns that meet the cost of equity or assets, which is below the typical performance of the biotechnology industry. The company's operating income was -613.96 million CNY, and net income was -297.77 million CNY, reflecting a challenging financial performance. Everest Medicines' revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risk if demand for its products in its primary market declines. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the negative operating and net income figures suggest that the company is not currently growing profitably. The company's capital expenditures of -348.34 million CNY indicate ongoing investment in its operations, but the negative sign suggests these are outflows. Risk factors for Everest Medicines include its negative operating cash flow and free cash flow, which could lead to liquidity constraints if not managed effectively. The company's dilution risk is assessed as low, with no significant dilution events reported in the available data. However, the company's negative net cash position after subtracting total debt is a key flag that investors should monitor. Recent events for Everest Medicines include analyst estimates that suggest a range of price targets from 40.70 CNY to 84.00 CNY, with a mean price target of 54.40 CNY and a median of 48.30 CNY. The mean recommendation from analysts is 2.14, indicating a generally positive outlook, with 2 strong-buy and 2 buy ratings.